Identification of predictive biomarkers of overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (I) with or without bevacizumab (B): Results from CALGB 90206 (Alliance).

Authors

Andrew B. Nixon

Duke University Medical Center, Durham, NC

Andrew B. Nixon , Susan Halabi , Ivo Shterev , Mark Starr , John C Brady , Janice P. Dutcher , Judith O. Hopkins , Herbert Hurwitz , Eric Jay Small , Brian I. Rini , Phillip G. Febbo , Daniel J. George

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2014 ASCO Annual Meeting

bookmark_border

Prognostic and predictive tumor-based biomarkers in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (IFN) with or without bevacizumab (Bev): Results from CALGB (Alliance) 90206.

First Author: Harriet M. Kluger

insert_chart_outlined

Poster

2021 Genitourinary Cancers Symposium

bookmark_border

Identification of prognostic and predictive biomarkers of overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with docetaxel, prednisone (DP) +/- bevacizumab (B) in CALGB 90401 (Alliance).

First Author: Susan Halabi

insert_chart_outlined

Poster

2017 ASCO Annual Meeting

bookmark_border

Association of on-treatment plasma HGF levels with overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (INF) +/- bevacizumab (BEV): Results from CALGB 90206 (Alliance).

First Author: Daniel J. George

insert_chart_outlined

Poster

2016 ASCO Annual Meeting

bookmark_border

Prognostic and predictive blood-based biomarkers (BMs) in patients (pts) with advanced epithelial ovarian cancer (EOC) treated with carboplatin–paclitaxel (CP) ± bevacizumab (BEV): Results from GOG-0218.

First Author: Angeles Alvarez Secord